Drug intelligence / Profile preview

TH-2205

Development stage: Unknown
Lead developer: Theratechnologies
Modality: Peptides

Overview

TH-2205 is an investigational drug candidate being developed by Theratechnologies, Inc. It is part of the company's SORT1+ Technology platform, which focuses on developing therapies for neoplasms. The drug is in the discovery phase and is designed to target the Sortilin (SORT1) receptor, which is highly expressed in various cancer cells and plays a crucial role in protein internalization, sorting, and trafficking. The overexpression of SORT1 in cancer is associated with aggressive disease and poor prognosis.

Targets

SORT1 (Sortilin)

Beyond the preview

Go deeper on TH-2205.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TH-2205.

Explore the full profile